vs

Side-by-side financial comparison of 1ST SOURCE CORP (SRCE) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $113.1M, roughly 1.3× 1ST SOURCE CORP). 1ST SOURCE CORP runs the higher net margin — 35.3% vs -5.5%, a 40.8% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 8.7%). 1ST SOURCE CORP produced more free cash flow last quarter ($58.1M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 7.8%).

1st Source Corporation is a financial services company headquartered in South Bend, Indiana. It operates 1st Source Bank, a bank with 81 branches in Indiana and Michigan. The bank's Specialty Finance Group provides financing for aircraft, trucks, and construction equipment. 1st Source Insurance provides insurance products and services.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SRCE vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$113.1M
SRCE
Growing faster (revenue YoY)
TARS
TARS
+119.6% gap
TARS
128.4%
8.7%
SRCE
Higher net margin
SRCE
SRCE
40.8% more per $
SRCE
35.3%
-5.5%
TARS
More free cash flow
SRCE
SRCE
$45.1M more FCF
SRCE
$58.1M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
7.8%
SRCE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
SRCE
SRCE
TARS
TARS
Revenue
$113.1M
$151.7M
Net Profit
$40.0M
$-8.4M
Gross Margin
Operating Margin
45.4%
-5.3%
Net Margin
35.3%
-5.5%
Revenue YoY
8.7%
128.4%
Net Profit YoY
6.5%
63.8%
EPS (diluted)
$1.63
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SRCE
SRCE
TARS
TARS
Q1 26
$113.1M
Q4 25
$110.8M
$151.7M
Q3 25
$110.7M
$118.7M
Q2 25
$108.2M
$102.7M
Q1 25
$104.0M
$78.3M
Q4 24
$97.8M
$66.4M
Q3 24
$97.9M
$48.1M
Q2 24
$97.3M
$40.8M
Net Profit
SRCE
SRCE
TARS
TARS
Q1 26
$40.0M
Q4 25
$41.1M
$-8.4M
Q3 25
$42.3M
$-12.6M
Q2 25
$37.3M
$-20.3M
Q1 25
$37.5M
$-25.1M
Q4 24
$31.4M
$-23.1M
Q3 24
$34.9M
$-23.4M
Q2 24
$36.8M
$-33.3M
Operating Margin
SRCE
SRCE
TARS
TARS
Q1 26
45.4%
Q4 25
-5.3%
Q3 25
49.7%
-12.2%
Q2 25
44.5%
-21.6%
Q1 25
45.8%
-33.5%
Q4 24
-36.8%
Q3 24
46.3%
-52.3%
Q2 24
49.1%
-81.6%
Net Margin
SRCE
SRCE
TARS
TARS
Q1 26
35.3%
Q4 25
37.1%
-5.5%
Q3 25
38.2%
-10.6%
Q2 25
34.5%
-19.8%
Q1 25
36.1%
-32.1%
Q4 24
32.1%
-34.8%
Q3 24
35.7%
-48.7%
Q2 24
37.8%
-81.6%
EPS (diluted)
SRCE
SRCE
TARS
TARS
Q1 26
$1.63
Q4 25
$1.67
$-0.17
Q3 25
$1.71
$-0.30
Q2 25
$1.51
$-0.48
Q1 25
$1.52
$-0.64
Q4 24
$1.27
$-0.57
Q3 24
$1.41
$-0.61
Q2 24
$1.49
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SRCE
SRCE
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.3B
$343.4M
Total Assets
$9.1B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SRCE
SRCE
TARS
TARS
Q1 26
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Total Debt
SRCE
SRCE
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
SRCE
SRCE
TARS
TARS
Q1 26
$1.3B
Q4 25
$1.3B
$343.4M
Q3 25
$1.2B
$335.1M
Q2 25
$1.2B
$332.6M
Q1 25
$1.2B
$342.5M
Q4 24
$1.1B
$224.5M
Q3 24
$1.1B
$237.5M
Q2 24
$1.0B
$252.2M
Total Assets
SRCE
SRCE
TARS
TARS
Q1 26
$9.1B
Q4 25
$9.1B
$562.2M
Q3 25
$9.1B
$534.6M
Q2 25
$9.1B
$495.0M
Q1 25
$9.0B
$500.8M
Q4 24
$8.9B
$377.0M
Q3 24
$8.8B
$376.3M
Q2 24
$8.9B
$376.8M
Debt / Equity
SRCE
SRCE
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SRCE
SRCE
TARS
TARS
Operating Cash FlowLast quarter
$59.1M
$19.3M
Free Cash FlowOCF − Capex
$58.1M
$13.0M
FCF MarginFCF / Revenue
51.4%
8.6%
Capex IntensityCapex / Revenue
0.9%
4.2%
Cash ConversionOCF / Net Profit
1.48×
TTM Free Cash FlowTrailing 4 quarters
$361.4M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SRCE
SRCE
TARS
TARS
Q1 26
$59.1M
Q4 25
$223.1M
$19.3M
Q3 25
$51.0M
$18.3M
Q2 25
$44.9M
$-29.4M
Q1 25
$71.8M
$-20.7M
Q4 24
$193.9M
$-22.2M
Q3 24
$68.4M
$-8.7M
Q2 24
$50.0M
$-14.4M
Free Cash Flow
SRCE
SRCE
TARS
TARS
Q1 26
$58.1M
Q4 25
$213.0M
$13.0M
Q3 25
$47.3M
$16.3M
Q2 25
$43.0M
$-30.4M
Q1 25
$69.3M
$-21.2M
Q4 24
$181.5M
$-22.3M
Q3 24
$66.7M
$-8.9M
Q2 24
$46.4M
$-15.4M
FCF Margin
SRCE
SRCE
TARS
TARS
Q1 26
51.4%
Q4 25
192.2%
8.6%
Q3 25
42.7%
13.8%
Q2 25
39.8%
-29.6%
Q1 25
66.6%
-27.1%
Q4 24
185.5%
-33.5%
Q3 24
68.1%
-18.6%
Q2 24
47.7%
-37.8%
Capex Intensity
SRCE
SRCE
TARS
TARS
Q1 26
0.9%
Q4 25
9.1%
4.2%
Q3 25
3.4%
1.6%
Q2 25
1.7%
1.0%
Q1 25
2.4%
0.8%
Q4 24
12.6%
0.1%
Q3 24
1.7%
0.6%
Q2 24
3.7%
2.5%
Cash Conversion
SRCE
SRCE
TARS
TARS
Q1 26
1.48×
Q4 25
5.42×
Q3 25
1.21×
Q2 25
1.20×
Q1 25
1.91×
Q4 24
6.17×
Q3 24
1.96×
Q2 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons